CIRM Funded Clinical Trials
Genetic Re-programming of Stem Cells to Fight Cancer
Disease Area:
Trial Sponsor:
Trial Stage:
Phase 1
Trial Status:
Closed
Targeted Enrollment:
5
ClinicalTrials.gov ID:
Details:
There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient’s own immune system cells and blood-forming stem cells with the aim of creating a continuous supply of immune cells that can recognize and attack hard-to-treat cancers.
Design:
Single dose.
Goal:
Primary: Safety and feasibility. Secondary: Persistence of gene-marked anti-cancer immune cells
